Velsera Technology Drives Advanced Cancer Diagnostics with FDA Approval of Illumina TruSight Oncology Comprehensive IVD
核心洞察
Velsera (搜索)'s tumor profiling technology is a key component of the knowledge base supporting the Illumina TruSight™ Oncology (搜索) (TSO) Comprehensive IVD results report, enhancing personalized treatment.
The collaboration between Velsera (搜索) and Illumina, started in 2018, aims to advance cancer (搜索) diagnostics and improve the accessibility of targeted therapeutics nationwide.
Velsera (搜索)'s Knowledge Base classifies cancer (搜索) mutations, enabling more personalized and effective treatment plans for patients, and facilitating NGS-based diagnostics adoption.
Velsera (搜索), a healthcare technology company, announced that its tumor profiling technology is a key component of the knowledge base supporting the Illumina TruSight™ Oncology (搜索) (TSO) Comprehensive IVD, which recently received FDA approval. This collaboration enhances patient care by enabling personalized treatment options nationwide.
The partnership between Velsera (搜索) and Illumina, which began in December 2018, was driven by a shared goal to advance cancer (搜索) diagnostics and enhance the accessibility of targeted therapeutics. Velsera's Knowledge Base (KB) is integral to the TSO Comprehensive test, empowering laboratories to adopt NGS-based diagnostics with greater ease and precision.
Key Role of Velsera's Knowledge Base
According to Nicki Berry, Head of Region-Americas at Illumina, the collaboration with Velsera (搜索) helped deliver the vision for the TruSight™ Oncology Comprehensive test, which provides laboratories with a clinically-optimized in vitro diagnostic (IVD) test that simplifies the identification of important cancer (搜索) biomarkers.
Velsera (搜索)'s KB content is crucial in classifying cancer (搜索) mutations into evidence of clinical significance or potential clinical significance, thereby enabling more personalized and effective treatment plans for patients. This classification aids in the selection of targeted therapies, improving patient outcomes.
Velsera's Commitment to Precision Medicine
Jamie Littlejohns, CEO of Velsera (搜索), stated that advancing cancer (搜索) diagnostics and making targeted therapeutics more accessible to healthcare systems, laboratories, and patients worldwide remains a key focus. This achievement reflects Velsera's commitment to accelerating the translation of research discoveries to improve patient outcomes. By working closely with Illumina, Velsera has contributed to making a cutting-edge diagnostic more accessible, which will now help more patients with cancer in the US.
Future Implications
As precision medicine advances, Velsera (搜索) is at the forefront, working with industry leaders like Illumina to revolutionize the diagnostics landscape. Together, Velsera and its collaborators are accelerating the path to market for IVD solutions and setting a new standard for the entire sequencing market, delivering faster and more precise biomarker identification that directly enhances patient care.